|Usually by mouth; intravenous|
|Metabolism||95%, mainly liver, also in blood and tissues|
|Onset of action||Within 5–15 min|
|Elimination half-life||30–60 minutes|
|Chemical and physical data|
|Molar mass||104.10 g/mol (GHB)|
126.09 g/mol (sodium salt)
142.19 g/mol (potassium salt)
|3D model (JSmol)|
γ-Hydroxybutyric acid (GHB), also known as 4-hydroxybutanoic acid, is a naturally occurring neurotransmitter and a psychoactive drug. It is a precursor to GABA, glutamate, and glycine in certain brain areas, it acts on the GHB receptor and it is a weak agonist at the GABAB receptor.
GHB has been used in a medical setting as a general anesthetic and as a treatment for cataplexy, narcolepsy, and alcoholism. It is also used illegally as an intoxicant, to try to increase athletic performance, and as a date rape drug and as a recreational drug. It is commonly used in the form of a salt, such as sodium γ-hydroxybutyrate (Na.GHB, sodium oxybate, or Xyrem) or potassium γ-hydroxybutyrate (K.GHB, potassium oxybate).
GHB is also produced as a result of fermentation, and is found in small quantities in some beers and wines, beef and small citrus fruits.
Succinic semialdehyde dehydrogenase deficiency is a disease that causes GHB to accumulate in the blood.
- 1 Medical use
- 2 Recreational use
- 3 Use as a date rape drug
- 4 Adverse effects
- 5 Overdose
- 6 Endogenous production
- 7 Natural fermentation by-product
- 8 Pharmacology
- 9 History
- 10 Legal status
- 11 See also
- 12 References
- 13 External links
GHB is the active ingredient in the prescription medication sodium oxybate (Xyrem). Sodium oxybate is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cataplexy associated with narcolepsy and excessive daytime sleepiness (EDS) associated with narcolepsy.
GHB is a central nervous system depressant used as an intoxicant. It has many street names. Its effects have been described anecdotally as comparable with ethanol (alcohol) and MDMA use, such as euphoria, disinhibition, enhanced libido and empathogenic states. At higher doses, GHB may induce nausea, dizziness, drowsiness, agitation, visual disturbances, depressed breathing, amnesia, unconsciousness, and death. When death is associated with GHB, it is sometimes in conjunction with other drugs, such as alcohol or benzodiazepine which influence the same neurotransmitter (gamma-aminobutyric acid, GABA). The effects of GHB can last from 1.5 to 4 hours, or longer if large doses have been consumed. Consuming GHB with alcohol can cause respiratory arrest and vomiting in combination with unrouseable sleep, which is a potentially lethal combination.
Recreational doses of 1-2 g generally provide a feeling of euphoria, and larger doses create deleterious effects such as reduced motor function and drowsiness. The sodium salt of GHB has a salty taste. Other salt forms such as calcium GHB and magnesium GHB have also been reported, but the sodium salt is by far the most common.
Some prodrugs convert to GHB in the stomach and blood stream, such as γ-butyrolactone (GBL). Other prodrugs, such as 1,4-butanediol (1,4-B), also have their own toxicity concerns. GBL and 1,4-B are normally found as pure liquids, but they may be mixed with other more harmful solvents when intended for industrial use, e.g., as paint stripper or varnish thinner.
GHB can be manufactured with little knowledge of chemistry, as it involves the mixing of its two precursors, GBL and an alkali hydroxide such as sodium hydroxide, to form the GHB salt. Due to the ease of manufacture and the availability of its precursors, it is not usually produced in illicit laboratories like other synthetic drugs, but in private homes by low level producers. While available as a prescription for the rare and severe forms of sleep disorder narcolepsy in most of Europe, GHB was banned in the U.S. by the FDA in 1990. However, on 17 July 2002, GHB was approved for treatment of cataplexy, often associated with narcolepsy. GHB is "colourless and odorless".
GHB has been used as a club drug, apparently starting in the 1990s, as small doses of GHB can act as a euphoriant and are believed to be aphrodisiac. GHB slang terms are liquid ecstasy, lollipops, liquid X or liquid E due to its tendency to produce euphoria and sociability and its use in the dance party scene.
By 2009 this use had diminished, possibly due to efforts to control distribution of GHB and its analogs, or to the narrow range of dosing and adverse effects of confusion, dizziness, blurred vision, hot/cold flushes, profuse sweating, vomiting, and loss of consciousness when overdosed. The downward trend was still apparent in 2012.:30–32
Sports and athletics
Some athletes have used GHB or analogs because they have been marketed as being anabolic agents, although there is no evidence that it builds muscle or improves performance in athletes.
Use as a date rape drug
GHB became known to the general public as a date rape drug by the late 1990s. GHB is colourless and odorless and has been described as "very easy to add to drinks". When unobtrusively administered in a drink the victim will quickly feel groggy and sleepy, and upon recovery may have an impaired ability to recall memories of events that occurred during the period of intoxication. Consequently, the evidence and the identification of the perpetrator of the rape is often difficult.
It is also difficult to establish how often GHB is used to facilitate rape as it is difficult to detect in a urine sample after a day, and many victims may only recall the rape some time after its occurrence.
However, a 2006 study suggested that there was "no evidence to suggest widespread date rape drug use" in the UK, and that less than 2% of cases involved GHB, while 17% involved cocaine, and a survey in the Netherlands published in 2010 found that the proportion of drug-related rape where GHB was used appeared to be greatly overestimated by the media.
There have been several high-profile cases of GHB as a date rape drug that received national attention in the United States. In early 1999, a 15-year-old girl, Samantha Reid of Rockwood, Michigan, died from GHB poisoning. Reid’s death inspired the legislation titled the "Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 2000". This is the law that made GHB a Schedule 1 controlled substance.
GHB can be detected in hair. Hair testing can be a useful tool in court cases or for the victim's own information. Over-the-counter urine test kits only test for date rape drugs that are benzodiazepines, and GHB is not a benzodiazepine. To detect GHB in urine, the sample must be taken within four hours of GHB ingestion, and cannot be tested at home.
Combination with alcohol
In humans, GHB has been shown to reduce the elimination rate of alcohol. This may explain the respiratory arrest that has been reported after ingestion of both drugs. A review of the details of 194 deaths attributed to or related to GHB over a ten-year period found that most were from respiratory depression caused by interaction with alcohol or other drugs.
One publication has investigated 226 deaths attributed to GHB. Of 226 deaths included, 213 had a cardiorespiratory arrest and 13 had fatal accidents. Seventy-one deaths (34%) had no co-intoxicants. Postmortem blood GHB was 18–4400 mg/L (median=347) in deaths negative for co-intoxicants.
One report has suggested that sodium oxybate overdose might be fatal, based on deaths of three patients who had been prescribed the drug. However, for two of the three cases, post-mortem GHB concentrations were 141 and 110 mg/L, which is within the expected range of concentrations for GHB after death, and the third case was a patient with a history of intentional drug overdose. The toxicity of GHB has been an issue in criminal trials, as in the death of Felicia Tang, where the defense argued that death was due to GHB, not murder.
GHB is produced in the body in very small amounts, and blood levels may climb after death to levels in the range of 30–50 mg/L. Levels higher than this are found in GHB deaths. Levels lower than this may be due to GHB or to postmortem endogenous elevations.
A UK parliamentary committee commissioned report found the use of GHB to be less dangerous than tobacco and alcohol in social harms, physical harm and addiction.
In multiple studies, GHB has been found to impair spatial memory, working memory, learning and memory in rats with chronic administration. These effects are associated with decreased NMDA receptor expression in the cerebral cortex and possibly other areas as well. In addition, the neurotoxicity appears to be caused by oxidative stress.
Although there have been reported fatalities due to GHB withdrawal, reports are inconclusive and further research is needed. A common problem is that GHB does not leave traces in the body after a short period of time, complicating diagnosis and research. Addiction occurs when repeated drug use disrupts the normal balance of brain circuits that control rewards, memory and cognition, ultimately leading to compulsive drug taking.
Rats forced to consume massive doses of GHB will intermittently prefer GHB solution to water but, after experiments on rats, it was noted that "no rat showed any sign of withdrawal when GHB was finally removed at the end of the 20-week period" or during periods of voluntary abstinence.
GHB has also been associated with a withdrawal syndrome of insomnia, anxiety, and tremor that usually resolves within three to twenty-one days. The withdrawal syndrome can be severe producing acute delirium and may require hospitalization in an intensive care unit for management. Management of GHB dependence involves considering the person's age, comorbidity and the pharmacological pathways of GHB. The mainstay of treatment for severe withdrawal is supportive care and benzodiazepines for control of acute delirium, but larger doses are often required compared to acute delirium of other causes (e.g. > 100 mg/d of diazepam). Baclofen has been suggested as an alternative or adjunct to benzodiazepines based on anecdotal evidence and some animal data. However, there is less experience with the use of baclofen for GHB withdrawal, and additional research in humans is needed. Baclofen was first suggested as an adjunct because benzodiazepines do not affect GABAB receptors and thus have no cross-tolerance with GHB while baclofen, which works via GABAB receptors, is cross-tolerant with GHB and may be more effective in alleviating withdrawal effects of GHB.
GHB withdrawal is not widely discussed in textbooks and some psychiatrists, general practitioners, and even hospital emergency physicians may not be familiar with this withdrawal syndrome.
Overdose of GHB can sometimes be difficult to treat because of its multiple effects on the body. GHB tends to cause rapid unconsciousness at doses above 3500 mg, with single doses over 7000 mg often causing life-threatening respiratory depression, and higher doses still inducing bradycardia and cardiac arrest. Other side-effects include convulsions (especially when combined with stimulants), and nausea/vomiting (especially when combined with alcohol).
The greatest life threat due to GHB overdose (with or without other substances) is respiratory arrest. Other relatively common causes of death due to GHB ingestion include aspiration of vomitus, positional asphyxia, and trauma sustained while intoxicated (e.g., motor vehicle accidents while driving under the influence of GHB). The risk of aspiration pneumonia and positional asphyxia risk can be reduced by laying the patient down in the recovery position. People are most likely to vomit as they become unconscious, and as they wake up. It is important to keep the victim awake and moving, who must not be left alone due to the risk of death through vomiting. Frequently they will be in a good mood but this does not mean they are not in danger. GHB overdose is a medical emergency and immediate assessment in an emergency department is needed.
Convulsions from GHB can be treated with the benzodiazepines diazepam or lorazepam. Even though these benzodiazepines are also CNS depressants, they primarily modulate GABAA receptors whereas GHB is primarily a GABAB receptor agonist, and so do not worsen CNS depression as much as might be expected.
Because of the faster and more complete absorption of GBL relative to GHB, its dose-response curve is steeper, and overdoses of GBL tend to be more dangerous and problematic than overdoses involving only GHB or 1,4-B. Any GHB/GBL overdose is a medical emergency and should be cared for by appropriately trained personnel.
A newer synthetic drug SCH-50911, which acts as a selective GABAB antagonist, quickly reverses GHB overdose in mice. However, this treatment has yet to be tried in humans, and it is unlikely that it will be researched for this purpose in humans due to the illegal nature of clinical trials of GHB, and the lack of medical indemnity coverage inherent in using an untested treatment for a life-threatening overdose.[original research?]
Detection of use
GHB may be quantitated in blood or plasma to confirm a diagnosis of poisoning in hospitalized patients, provide evidence in an impaired driving arrest or to assist in a medicolegal death investigation. Blood or plasma GHB concentrations are usually in a range of 50–250 mg/L in persons receiving the drug therapeutically (during general anesthesia), 30–100 mg/L in those arrested for impaired driving, 50–500 mg/L in acutely intoxicated patients and 100–1000 mg/L in victims of fatal overdosage. Urine is often the preferred specimen for routine drug abuse monitoring purposes. Both γ-butyrolactone (GBL) and 1,4-butanediol are converted to GHB in the body.
In January 2016, it was announced scientists had developed a way to detect GHB, among other things, in saliva.
Cells produce GHB by reduction of succinic semialdehyde via succinic semialdehyde reductase (SSR). This enzyme appears to be induced by cAMP levels, meaning substances that elevate cAMP, such as forskolin and vinpocetine, may increase GHB synthesis and release. Conversely, endogeneous GHB production in those taking valproic acid will be inhibited via inhibition of the conversion from succinic acid semialdehyde to GHB. It is important to note, however, that direct administration of GHB or endogenous GHB already present in the body will not be affected by valproic acid. People with the disorder known as succinic semialdehyde dehydrogenase deficiency, also known as γ-hydroxybutyric aciduria, have elevated levels of GHB in their urine, blood plasma and cerebrospinal fluid.
The precise function of GHB in the body is not clear. It is known, however, that the brain expresses a large amount of receptors that are activated by GHB. These receptors are excitatory and not responsible for the sedative effects of GHB – they have been shown to elevate the principal excitatory neurotransmitter—glutamate. The benzamide antipsychotics—amisulpride, sulpiride—have been shown to bind to this receptor in vivo. Other antipsychotics were tested and were not found to have an affinity for this receptor.
Natural fermentation by-product
GHB is also produced as a result of fermentation and so is found in small quantities in some beers and wines, in particular fruit wines. The amount found in wine is pharmacologically insignificant and not sufficient to produce psychoactive effects.
GHB has at least two distinct binding sites in the central nervous system. GHB is an agonist at the newly characterized GHB receptor, which is excitatory, and it is a weak agonist at the GABAB receptor, which is inhibitory. GHB is a naturally occurring substance that acts in a similar fashion to some neurotransmitters in the mammalian brain. GHB is probably synthesized from GABA in GABAergic neurons, and released when the neurons fire.
GHB induces the accumulation of either a derivative of tryptophan or tryptophan itself in the extracellular space, possibly by increasing tryptophan transport across the blood–brain barrier. The blood content of certain neutral amino-acids, including tryptophan, is also increased by peripheral GHB administration. GHB-induced stimulation of tissue serotonin turnover may be due to an increase in tryptophan transport to the brain and in its uptake by serotonergic cells. As the serotonergic system may be involved in the regulation of sleep, mood, and anxiety, the stimulation of this system by high doses of GHB may be involved in certain neuropharmacological events induced by GHB administration.
However, at therapeutic doses, GHB reaches much higher concentrations in the brain and activates GABAB receptors, which are primarily responsible for its sedative effects. GHB's sedative effects are blocked by GABAB antagonists.
The role of the GHB receptor in the behavioural effects induced by GHB is more complex. GHB receptors are densely expressed in many areas of the brain, including the cortex and hippocampus, and these are the receptors that GHB displays the highest affinity for. There has been somewhat limited research into the GHB receptor; however, there is evidence that activation of the GHB receptor in some brain areas results in the release of glutamate, the principal excitatory neurotransmitter. Drugs that selectively activate the GHB receptor cause absence seizures in high doses, as do GHB and GABA(B) agonists.
Activation of both the GHB receptor and GABA(B) is responsible for the addictive profile of GHB. GHB's effect on dopamine release is biphasic. Low concentrations stimulate dopamine release via the GHB receptor. Higher concentrations inhibit dopamine release via GABA(B) receptors as do other GABA(B) agonists such as baclofen and phenibut. After an initial phase of inhibition, dopamine release is then increased via the GHB receptor. Both the inhibition and increase of dopamine release by GHB are inhibited by opioid antagonists such as naloxone and naltrexone. Dynorphin may play a role in the inhibition of dopamine release via kappa opioid receptors.
This explains the paradoxical mix of sedative and stimulatory properties of GHB, as well as the so-called "rebound" effect, experienced by individuals using GHB as a sleeping agent, wherein they awake suddenly after several hours of GHB-induced deep sleep. That is to say that, over time, the concentration of GHB in the system decreases below the threshold for significant GABAB receptor activation and activates predominantly the GHB receptor, leading to wakefulness.
Recently, analogs of GHB, such as 4-hydroxy-4-methylpentanoic acid (UMB68) have been synthesised and tested on animals, in order to gain a better understanding of GHB's mode of action. Analogues of GHB such as 3-methyl-GHB, 4-methyl-GHB, and 4-phenyl-GHB have been shown to produce similar effects to GHB in some animal studies, but these compounds are even less well researched than GHB itself. Of these analogues, only 4-methyl-GHB (γ-hydroxyvaleric acid, GHV) and a prodrug form γ-valerolactone (GVL) have been reported as drugs of abuse in humans, and on the available evidence seem to be less potent but more toxic than GHB, with a particular tendency to cause nausea and vomiting.
Other prodrug ester forms of GHB have also rarely been encountered by law enforcement, including 1,4-butanediol diacetate (BDDA/DABD), methyl-4-acetoxybutanoate (MAB), and ethyl-4-acetoxybutanoate (EAB), but these are, in general, covered by analogue laws in jurisdictions where GHB is illegal, and little is known about them beyond their delayed onset and longer duration of action. The intermediate compound γ-hydroxybutyraldehyde (GHBAL) is also a prodrug for GHB; however, as with all aliphatic aldehydes this compound is caustic and is strong-smelling and foul-tasting; actual use of this compound as an intoxicant is likely to be unpleasant and result in severe nausea and vomiting.
Both of the metabolic breakdown pathways shown for GHB can run in either direction, depending on the concentrations of the substances involved, so the body can make its own GHB either from GABA or from succinic semialdehyde. Under normal physiological conditions, the concentration of GHB in the body is rather low, and the pathways would run in the reverse direction to what is shown here to produce endogenous GHB. However, when GHB is consumed for recreational or health promotion purposes, its concentration in the body is much higher than normal, which changes the enzyme kinetics so that these pathways operate to metabolise GHB rather than producing it.
Alexander Zaytsev worked on this chemical family and published work on it in 1874.:79 The first extended research into GHB and its use in humans was conducted in the early 1960s by Dr. Henri Laborit to use in studying the neurotransmitter GABA.:11–12 It was studied in a range of uses including obstetric surgery and during childbirth and as an anxiolytic; there were anecdotal reports of it having antidepressant and aphrodisiac effects as well.:27 It was also studied as an intraveuous anesthetic agent and was marketed for that purpose starting in 1964 in Europe but it was not widely adopted as it caused seizures; as of 2006 that use was still authorized in France and Italy but not widely used.:27–28 It was also studied to treat alcohol addiction; while the evidence for this use is weak,:28–29 however sodium oxybate is marketed for this use in Italy.
In May 1990 GHB was introduced as a dietary supplement and was marketed to body builders, for help with weight control and as a sleep aid, and as a "replacement" for l-tryptophan, which was removed from the market in November 1989 when batches of it were found to cause eosinophilia-myalgia syndrome. By November of that year 57 cases of illness caused by the GHB supplements had been reported to the Centers for Disease Control and Prevention, with people having taken up to three teaspoons of GHB; there were no deaths but nine people needed care in an intensive care unit. The FDA issued a warning in November 1990 that sale of GHB was illegal. GHB continued to be manufactured and sold illegally and it and analogs were adopted as a club drug and came to be used as a date rape drug, and the DEA made seizures and the FDA reissued warnings several times throughout the 1990s.
At the same time, research on the use of GHB in the form of sodium oxybate had formalized, as a company called Orphan Medical had filed an investigational new drug application and was running clinical trials with the intention of gaining regulatory approval for use to treat narcolepsy.:18–25;28:10
A popular children's toy, Bindeez (also known as Aqua Dots, in the United States), produced by Melbourne company Moose, was banned in Australia in early November 2007 when it was discovered that 1,4-butanediol (1,4-B), which is metabolized into GHB, had been substituted for the non-toxic plasticiser 1,5-pentanediol in the bead manufacturing process. Three young children were hospitalized as a result of ingesting a large number of the beads, and the toy was recalled.
In the United States, GHB was placed on Schedule I of the Controlled Substances Act in March 2000. However, used in sodium oxybate under an IND or NDA from the US FDA, it is considered a Schedule III substance but with Schedule I trafficking penalties, one of several drugs that are listed in multiple schedules.
In the UK GHB was made a class C drug in June 2003. In October 2013 the ACMD recommended upgrading it from schedule IV to schedule II in line with UN recommendations. Their report concluded that the minimal use of Xyrem in the UK meant that prescribers would be minimally inconvenienced by the rescheduling. This advice was followed and GHB was moved to schedule 2 on 7 January 2015.
In Hong Kong, GHB is regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. It can only be used legally by health professionals and for university research purposes. The substance can be given by pharmacists under a prescription. Anyone who supplies the substance without prescription can be fined HK$10,000. The penalty for trafficking or manufacturing the substance is a HK$150,000 fine and life imprisonment. Possession of the substance for consumption without license from the Department of Health is illegal with a HK$100,000 fine or 5 years of jail time.
In New Zealand and Australia, GHB, 1,4-B and GBL are all Class B illegal drugs, along with any possible esters, ethers and aldehydes. GABA itself is also listed as an illegal drug in these jurisdictions, which seems unusual given its failure to cross the blood–brain barrier, but there was a perception among legislators that all known analogues should be covered as far as this was possible. Attempts to circumvent the illegal status of GHB have led to the sale of derivatives such as 4-methyl-GHB (γ-hydroxyvaleric acid, GHV) and its prodrug form γ-valerolactone (GVL), but these are also covered under the law by virtue of their being "substantially similar" to GHB or GBL and; so importation, sale, possession and use of these compounds is also considered to be illegal.
In Chile, GHB is a controlled drug under the law Ley de substancias psicotrópicas y estupefacientes (psychotropic substances and narcotics).
- Riviello, Ralph J. (2010). Manual of forensic emergency medicine : a guide for clinicians. Sudbury, Mass.: Jones and Bartlett Publishers. p. 42. ISBN 9780763744625.
- "Sodium Oxybate: MedlinePlus Drug Information". Nlm.nih.gov. 28 July 2010. Retrieved 2010-08-01.
- Benzer, Theodore I (8 January 2007). "Toxicity, Gamma-Hydroxybutyrate". eMedicine.
- US Drug Enforcement Administration. "GHB, GBL and 1,4BD as Date Rape Drugs". Archived from the original on 10 May 2012. Retrieved 2012-05-10.
- Weil A, Rosen W (1993). "Depressants". From Chocolate to Morphine (2nd ed.). Boston/New York: Houghton Mifflin Company. p. 77. ISBN 978-0-395-66079-9.
- Mayer G (May 2012). "The use of sodium oxybate to treat narcolepsy". Expert Review of Neurotherapeutics. 12 (5): 519–29. doi:10.1586/ern.12.42. PMID 22550980.
- Caputo F, Mirijello A, Cibin M, Mosti A, Ceccanti M, Domenicali M, Bernardi M, Maremmani I, Addolorato G (April 2015). "Novel strategies to treat alcohol dependence with sodium oxybate according to clinical practice". European Review for Medical and Pharmacological Sciences. 19 (7): 1315–20. PMID 25912595.
- Keating GM (January 2014). "Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence". Clinical Drug Investigation. 34 (1): 63–80. doi:10.1007/s40261-013-0158-x. PMID 24307430.
- Calandre EP, Rico-Villademoros F, Slim M (June 2015). "An update on pharmacotherapy for the treatment of fibromyalgia". Expert Opinion on Pharmacotherapy. 16 (9): 1347–68. doi:10.1517/14656566.2015.1047343. PMID 26001183.
- Staud R (August 2011). "Sodium oxybate for the treatment of fibromyalgia". Expert Opinion on Pharmacotherapy. 12 (11): 1789–98. doi:10.1517/14656566.2011.589836. PMID 21679091.
- "FDA Approval Letter for Xyrem; Indication: Cataplexy associated with narcolepsy; 17 July 2002" (PDF).
- "FDA Approval Letter for Xyrem; Indication: EDS (Excessive Daytime Sleepiness) associated with narcolepsy; 18 November 2005" (PDF).
- Scrima L, Hartman PG, Johnson FH, Thomas EE, Hiller FC (December 1990). "The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study". Sleep. 13 (6): 479–90. PMID 2281247.
- Scrima L, Johnson FH, Hiller FC (1991). "Long-Term Effect of Gamma-Hydroxybutyrate on Sleep in Narcolepsy Patients". Sleep Research. 20: 330.
- Van Cauter E, Plat L, Scharf MB, Leproult R, Cespedes S, L'Hermite-Balériaux M, Copinschi G (August 1997). "Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young Men". The Journal of Clinical Investigation. 100 (3): 745–53. doi:10.1172/JCI119587. PMC 508244. PMID 9239423.
- Scrima L, Shander D (January 24, 1991). "Letter to Editor on article: Re: Narcolepsy Review (Aldrich MS: 8-9-91)". New England Journal of Medicine. 324 (4): 270–271.
- Scrima L, Hartman PG, Johnson FH, Thomas EE, Hiller FC (December 1990). "The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study". Sleep. 13 (6): 479–90. PMID 2281247.
- Nutt D, King LA, Saulsbury W, Blakemore C (March 2007). "Development of a rational scale to assess the harm of drugs of potential misuse". Lancet. 369 (9566): 1047–53. doi:10.1016/s0140-6736(07)60464-4. PMID 17382831.
- Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B (July 2012). "The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol". Clinical Toxicology. 50 (6): 458–70. doi:10.3109/15563650.2012.702218. PMID 22746383.
- Galloway GP, Frederick-Osborne SL, Seymour R, Contini SE, Smith DE (April 2000). "Abuse and therapeutic potential of gamma-hydroxybutyric acid". Alcohol. 20 (3): 263–9. doi:10.1016/S0741-8329(99)00090-7. PMID 10869868.
- Thai D, Dyer JE, Benowitz NL, Haller CA (October 2006). "Gamma-hydroxybutyrate and ethanol effects and interactions in humans". Journal of Clinical Psychopharmacology. 26 (5): 524–9. doi:10.1097/01.jcp.0000237944.57893.28. PMC 2766839. PMID 16974199.
- "The Vaults Of Erowid". Erowid.org (18 March 2009). Retrieved on 2012-09-27.
- Busardò FP, Jones AW (January 2015). "GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome". Current Neuropharmacology. 13 (1): 47–70. doi:10.2174/1570159X13666141210215423. PMC 4462042. PMID 26074743.
- US 4393236, Klosa, Joseph, "Production of nonhygroscopic salts of 4-hydroxybutyric acid", issued 1983-07-12
- Jones C (June 2001). "Suspicious death related to gamma-hydroxybutyrate (GHB) toxicity". Journal of Clinical Forensic Medicine. 8 (2): 74–6. doi:10.1054/jcfm.2001.0473. PMID 15274975.
- Kam PC, Yoong FF (December 1998). "Gamma-hydroxybutyric acid: an emerging recreational drug". Anaesthesia. 53 (12): 1195–8. doi:10.1046/j.1365-2044.1998.00603.x. PMID 10193223.
In the UK, GHB has been available in the night clubs around London since 1994...
- Rodriguez D, Della Gaspera B, Zalc B, Hauw JJ, Fontaine B, Edan G, Clanet M, Dautigny A, Pham-Dinh D (December 1997). "Identification of a Val 145 Ile substitution in the human myelin oligodendrocyte glycoprotein: lack of association with multiple sclerosis. The Réseau de Recherche Clinique INSERM sur la Susceptibilité Génétique à la Sclérose en Plaques". Multiple Sclerosis. 3 (6): 377–81. doi:10.1177/135245859700300603. PMC 2713368. PMID 9493637.
- Klein M, Kramer F (February 2004). "Rave drugs: pharmacological considerations". AANA Journal. 72 (1): 61–7. PMID 15098519.
- "Critical review of gamma-hydroxybutyric acid (GHB)" (PDF). 2012.
- Press, The Associated (12 May 1999). "Warning on Risk of 'Party Drug' Chemicals". The New York Times.
- Németh Z, Kun B, Demetrovics Z (September 2010). "The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review". Journal of Psychopharmacology. 24 (9): 1281–7. doi:10.1177/0269881110363315. PMID 20488831.
- ElSohly MA, Salamone SJ (1999). "Prevalence of drugs used in cases of alleged sexual assault". Journal of Analytical Toxicology. 23 (3): 141–6. doi:10.1093/jat/23.3.141. PMID 10369321.
- Alcohol and other popular Date Rape Drugs. udel.edu
- "Labs making date-rape drug raided", The Independent, 10 July 2008.
- "No evidence to suggest widespread date rape drug use'". 2006-11-16. Archived from the original on 2009-01-08. Retrieved 2014-04-08.
- "Date-rape drugs 'not widespread'". BBC News. 2006-11-16. Retrieved 2014-04-08.
- Martin, Jackie Harrison (16 January 2009). REMEMBERING SAMANTHA REID: 10th anniversary of teen's GHB death. thenewsherald.com. Retrieved on 2012-09-27.
- Testing for GHB in Hair by GC/MS/MS after a Single Exposure. Application to Document Sexual assault Archived 24 December 2012 at the Wayback Machine. 24 December 2012 at the Wayback Machine. University of Hawaii. Jan 2003. Last accessed 4 Jan 2011.
- "Drink Speaks the Truth: Forensic Investigation of Drug Facilitated Sexual Assaults".
- Lott S, Piper T, Mehling L, Spottke A, Maas A, Thevis M, Madea B, Hess C (2015). "Measurement of exogenous gamma-hydroxybutyric acid (GHB) in urine using isotope ratio mass spectrometry (IRMS)" (PDF). Toxichem Krimtech. 82: 264.
- Poldrugo F, Addolorato G (1999). "The role of gamma-hydroxybutyric acid in the treatment of alcoholism: from animal to clinical studies". Alcohol and Alcoholism. 34 (1): 15–24. doi:10.1093/alcalc/34.1.15. PMID 10075397.
- Zvosec et al. Proceedings of the American Academy of Forensic Science in Seattle, 2006. Web.archive.org (3 December 2007). Retrieved on 2011-12-24.
- Zvosec DL, Smith SW, Porrata T, Strobl AQ, Dyer JE (March 2011). "Case series of 226 γ-hydroxybutyrate-associated deaths: lethal toxicity and trauma". The American Journal of Emergency Medicine. 29 (3): 319–32. doi:10.1016/j.ajem.2009.11.008. PMID 20825811.
- Zvosec DL, Smith SW, Hall BJ (April 2009). "Three deaths associated with use of Xyrem". Sleep Medicine. 10 (4): 490–3. doi:10.1016/j.sleep.2009.01.005. PMID 19269893.
- Feldman NT (April 2009). "Xyrem safety: the debate continues". Sleep Medicine. 10 (4): 405–6. doi:10.1016/j.sleep.2009.02.002. PMID 19332385.
- Zvosec DL, Smith SW (January 2010). "Response to Editorial: "Xyrem safety: The debate continues"". Sleep Medicine. 11 (1): 108, author reply 108–9. doi:10.1016/j.sleep.2009.08.004. PMID 19959395.
- Drug classification: making a hash of it? House of Commons, Science and Technology Committee. Fifth Report of Session 2005–06 (31 July 2006)
- Sircar R, Basak A (December 2004). "Adolescent gamma-hydroxybutyric acid exposure decreases cortical N-methyl-D-aspartate receptor and impairs spatial learning". Pharmacology Biochemistry and Behavior. 79 (4): 701–8. doi:10.1016/j.pbb.2004.09.022. PMID 15582677.
- García FB, Pedraza C, Arias JL, Navarro JF (August 2006). "[Effects of subchronic administration of gammahydroxybutyrate (GHB) on spatial working memory in rats]". Psicothema (in Spanish). 18 (3): 519–24. PMID 17296081.
- Sircar R, Basak A, Sircar D (October 2008). "Gamma-hydroxybutyric acid-induced cognitive deficits in the female adolescent rat". Annals of the New York Academy of Sciences. 1139 (1): 386–9. doi:10.1196/annals.1432.044. PMID 18991885.
- Sgaravatti AM, Sgarbi MB, Testa CG, Durigon K, Pederzolli CD, Prestes CC, Wyse AT, Wannmacher CM, Wajner M, Dutra-Filho CS (February 2007). "Gamma-hydroxybutyric acid induces oxidative stress in cerebral cortex of young rats". Neurochemistry International. 50 (3): 564–70. doi:10.1016/j.neuint.2006.11.007. PMID 17197055.
- Sgaravatti AM, Magnusson AS, Oliveira AS, Mescka CP, Zanin F, Sgarbi MB, Pederzolli CD, Wyse AT, Wannmacher CM, Wajner M, Dutra-Filho CS (June 2009). "Effects of 1,4-butanediol administration on oxidative stress in rat brain: study of the neurotoxicity of gamma-hydroxybutyric acid in vivo". Metabolic Brain Disease. 24 (2): 271–82. doi:10.1007/s11011-009-9136-7. PMID 19296210.
- Galloway GP, Frederick SL, Staggers FE, Gonzales M, Stalcup SA, Smith DE (January 1997). "Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence". Addiction. 92 (1): 89–96. doi:10.1111/j.1360-0443.1997.tb03640.x. PMID 9060200.
- "GHB Rehab and Treatment Options - AddictionResource".
- Department of Health and Human Services, SAMHSA Office of Applied Studies 2005 National Survey on Drug Use and Health (ages 12 years and up); American Heart Association; Johns Hopkins University study, Principles of Addiction Medicine; Psychology Today; National Gambling Impact Commission Study; National Council on Problem Gambling; Illinois Institute for Addiction Recovery; Society for Advancement of Sexual Health; All Psych Journal
- Addiction and the Brain. Time
- Colombo G, Agabio R, Balaklievskaia N, Diaz G, Lobina C, Reali R, Gessa GL (October 1995). "Oral self-administration of gamma-hydroxybutyric acid in the rat". European Journal of Pharmacology. 285 (1): 103–7. doi:10.1016/0014-2999(95)00493-5. PMID 8846805.
- Is GHB toxic? Addictive? Dangerous? lycaeum.org
- "GHB: An Important Pharmacologic and Clinical Update". Ualberta.ca. Retrieved 2010-08-01.
- Santos C, Olmedo RE (March 2017). "Sedative-Hypnotic Drug Withdrawal Syndrome: Recognition And Treatment". Emergency Medicine Practice. 19 (3): 1–20. PMID 28186869.
- LeTourneau JL, Hagg DS, Smith SM (2008). "Baclofen and gamma-hydroxybutyrate withdrawal". Neurocritical Care. 8 (3): 430–3. doi:10.1007/s12028-008-9062-2. PMC 2630388. PMID 18266111.
- Carter LP, Koek W, France CP (January 2009). "Behavioral analyses of GHB: receptor mechanisms". Pharmacology & Therapeutics. 121 (1): 100–14. doi:10.1016/j.pharmthera.2008.10.003. PMC 2631377. PMID 19010351.
- van Noorden MS, van Dongen LC, Zitman FG, Vergouwen TA (2009). "Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known". General Hospital Psychiatry. 31 (4): 394–6. doi:10.1016/j.genhosppsych.2008.11.001. PMID 19555805.
- Allen L, Alsalim W (April 2006). "Best evidence topic report. Gammahydroxybutyrate overdose and physostigmine". Emergency Medicine Journal. 23 (4): 300–1. doi:10.1136/emj.2006.035139. PMC 2579509. PMID 16549578.
- Michael H, Harrison M (January 2005). "Best evidence topic report: endotracheal intubation in gamma-hydroxybutyric acid intoxication and overdose". Emergency Medicine Journal. 22 (1): 43. doi:10.1136/emj.2004.021154. PMC 1726538. PMID 15611542.
- Erowid GHB Vault : Legal Status.
- Carai MA, Colombo G, Gessa GL (June 2005). "Resuscitative effect of a gamma-aminobutyric acid B receptor antagonist on gamma-hydroxybutyric acid mortality in mice". Annals of Emergency Medicine. 45 (6): 614–9. doi:10.1016/j.annemergmed.2004.12.013. PMID 15940094.
- Couper FJ, Thatcher JE, Logan BK (September 2004). "Suspected GHB overdoses in the emergency department". Journal of Analytical Toxicology. 28 (6): 481–4. doi:10.1093/jat/28.6.481. PMID 15516299.
- Marinetti LJ, Isenschmid DS, Hepler BR, Kanluen S (2005). "Analysis of GHB and 4-methyl-GHB in postmortem matrices after long-term storage". Journal of Analytical Toxicology. 29 (1): 41–7. doi:10.1093/jat/29.1.41. PMID 15808012.
- R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 680–684.
- "New spit test for 'date rape' drug developed in the UK".
- Kemmel V, Taleb O, Perard A, Andriamampandry C, Siffert JC, Mark J, Maitre M (October 1998). "Neurochemical and electrophysiological evidence for the existence of a functional gamma-hydroxybutyrate system in NCB-20 neurons". Neuroscience. 86 (3): 989–1000. doi:10.1016/S0306-4522(98)00085-2. PMID 9692734.
- Levy, et al. Antiepileptic drugs. . Retrieved 5 December 2016.
- National Organization for Rare Disorders. Succinic Semialdehyde Dehydrogenase Deficiency. Retrieved 6 March 2010.
- Andriamampandry C, Taleb O, Viry S, Muller C, Humbert JP, Gobaille S, Aunis D, Maitre M (September 2003). "Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB)". FASEB Journal. 17 (12): 1691–3. doi:10.1096/fj.02-0846fje. PMID 12958178.
- Castelli MP, Ferraro L, Mocci I, Carta F, Carai MA, Antonelli T, Tanganelli S, Cignarella G, Gessa GL (November 2003). "Selective gamma-hydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of gamma-hydroxybutyric acid". Journal of Neurochemistry. 87 (3): 722–32. doi:10.1046/j.1471-4159.2003.02037.x. PMID 14535954.
- Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V (April 1994). "Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics". European Journal of Pharmacology. 256 (2): 211–4. doi:10.1016/0014-2999(94)90248-8. PMID 7914168.
- Gobaille S, Hechler V, Andriamampandry C, Kemmel V, Maitre M (July 1999). "gamma-Hydroxybutyrate modulates synthesis and extracellular concentration of gamma-aminobutyric acid in discrete rat brain regions in vivo". The Journal of Pharmacology and Experimental Therapeutics. 290 (1): 303–9. PMID 10381791.
- Ottani A, Saltini S, Bartiromo M, Zaffe D, Renzo Botticelli A, Ferrari A, Bertolini A, Genedani S (October 2003). "Effect of gamma-hydroxybutyrate in two rat models of focal cerebral damage". Brain Research. 986 (1–2): 181–90. doi:10.1016/S0006-8993(03)03252-9. PMID 12965243.
- Elliott S, Burgess V (July 2005). "The presence of gamma-hydroxybutyric acid (GHB) and gamma-butyrolactone (GBL) in alcoholic and non-alcoholic beverages". Forensic Science International. 151 (2–3): 289–92. doi:10.1016/j.forsciint.2005.02.014. PMID 15939164.
- Wu Y, Ali S, Ahmadian G, Liu CC, Wang YT, Gibson KM, Calver AR, Francis J, Pangalos MN, Carter Snead O (December 2004). "Gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence". Neuropharmacology. 47 (8): 1146–56. doi:10.1016/j.neuropharm.2004.08.019. PMID 15567424.
- Cash CD, Gobaille S, Kemmel V, Andriamampandry C, Maitre M (December 1999). "Gamma-hydroxybutyrate receptor function studied by the modulation of nitric oxide synthase activity in rat frontal cortex punches". Biochemical Pharmacology. 58 (11): 1815–9. doi:10.1016/S0006-2952(99)00265-8. PMID 10571257.
- Maitre M, Humbert JP, Kemmel V, Aunis D, Andriamampandry C (March 2005). "[A mechanism for gamma-hydroxybutyrate (GHB) as a drug and a substance of abuse]". Medecine Sciences (in French). 21 (3): 284–9. doi:10.1051/medsci/2005213284. PMID 15745703.
- Waszkielewicz A, Bojarski J (2004). "Gamma-hydrobutyric acid (GHB) and its chemical modifications: a review of the GHBergic system" (PDF). Polish Journal of Pharmacology. 56 (1): 43–9. PMID 15047976.
- McGregor IS, Callaghan PD, Hunt GE (May 2008). "From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?". British Journal of Pharmacology. 154 (2): 358–68. doi:10.1038/bjp.2008.132. PMC 2442436. PMID 18475254.
- Kuriyama K, Sze PY (January 1971). "Blood-brain barrier to H3-gamma-aminobutyric acid in normal and amino oxyacetic acid-treated animals". Neuropharmacology. 10 (1): 103–8. doi:10.1016/0028-3908(71)90013-X. PMID 5569303.
- Dimitrijevic N, Dzitoyeva S, Satta R, Imbesi M, Yildiz S, Manev H (September 2005). "Drosophila GABA(B) receptors are involved in behavioral effects of gamma-hydroxybutyric acid (GHB)". European Journal of Pharmacology. 519 (3): 246–52. doi:10.1016/j.ejphar.2005.07.016. PMID 16129424.
- Banerjee PK, Snead OC (June 1995). "Presynaptic gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB (GABAB) receptor-mediated release of GABA and glutamate (GLU) in rat thalamic ventrobasal nucleus (VB): a possible mechanism for the generation of absence-like seizures induced by GHB". The Journal of Pharmacology and Experimental Therapeutics. 273 (3): 1534–43. PMID 7791129.
- Hechler V, Gobaille S, Bourguignon JJ, Maitre M (March 1991). "Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdialysis study". Journal of Neurochemistry. 56 (3): 938–44. doi:10.1111/j.1471-4159.1991.tb02012.x. PMID 1847191.
- Maitre M, Hechler V, Vayer P, Gobaille S, Cash CD, Schmitt M, Bourguignon JJ (November 1990). "A specific gamma-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties". The Journal of Pharmacology and Experimental Therapeutics. 255 (2): 657–63. PMID 2173754.
- Smolders I, De Klippel N, Sarre S, Ebinger G, Michotte Y (September 1995). "Tonic GABA-ergic modulation of striatal dopamine release studied by in vivo microdialysis in the freely moving rat". European Journal of Pharmacology. 284 (1–2): 83–91. doi:10.1016/0014-2999(95)00369-V. PMID 8549640.
- Mamelak M (1989). "Gammahydroxybutyrate: an endogenous regulator of energy metabolism". Neuroscience and Biobehavioral Reviews. 13 (4): 187–98. doi:10.1016/S0149-7634(89)80053-3. PMID 2691926.
- Wu H, Zink N, Carter LP, Mehta AK, Hernandez RJ, Ticku MK, Lamb R, France CP, Coop A (May 2003). "A tertiary alcohol analog of gamma-hydroxybutyric acid as a specific gamma-hydroxybutyric acid receptor ligand". The Journal of Pharmacology and Experimental Therapeutics. 305 (2): 675–9. doi:10.1124/jpet.102.046797. PMID 12606613.
- Lewis, David E. (2012). "Section 4.4.3 Aleksandr Mikhailovich Zaitsev". Early Russian organic chemists and their legacy. Springer. ISBN 9783642282195.
- Saytzeff, Alexander (1874). "Über die Reduction des Succinylchlorids". Liebigs Annalen der Chemie (in German). 171 (2): 258–290. doi:10.1002/jlac.18741710216.
- Laborit H, Jouany JM, Gerard J, Fabiani F (October 1960). "[Generalities concerning the experimental study and clinical use of gamma hydroxybutyrate of Na]". Agressologie (in French). 1: 397–406. PMID 13758011.
- "Alcover: Riassunto delle Caratteristiche del Prodotto". Agenzia Italiana del Farmaco. 31 March 2017. Index page
- Centers for Disease Control (CDC) (November 1990). "Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate". MMWR. Morbidity and Mortality Weekly Report. 39 (47): 861–3. PMID 2122223.
- Dyer JE (July 1991). "gamma-Hydroxybutyrate: a health-food product producing coma and seizurelike activity". The American Journal of Emergency Medicine. 9 (4): 321–4. PMID 2054002.
- Institute of Medicine; National Research Council (US) Committee on the Framework for Evaluating the Safety of Dietary Supplements (2002). "Appendix D: Table of Food and Drug Administration Actions on Dietary Supplements". Proposed Framework for Evaluating the Safety of Dietary Supplements: For Comment. National Academies Press (US).
- "GHB: A Club Drug To Watch" (PDF). Substance Abuse Treatment Advisory. 2 (1). November 2002. Archived from the original (PDF) on 1 August 2017. Retrieved 16 April 2018.
- Mason PE, Kerns WP (July 2002). "Gamma hydroxybutyric acid (GHB) intoxication". Academic Emergency Medicine. 9 (7): 730–9. doi:10.1197/aemj.9.7.730. PMID 12093716.
- "Transcript: FDA Peripheral and Central Nervous System Drugs Advisory Committee Meeting". FDA. 6 June 2001.
- Perry M, Pomfret J, Crabb RP (7 November 2007). "Australia bans China-made toy on toxic drug risk". Reuters.
- "2000 - Addition of Gamma-Hydroxybutyric Acid to Schedule I". US Department of Justice via the Federal Register. March 13, 2000.
- "William J. Clinton: Statement on Signing the Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 2000". February 18, 2000.
- "Gamma Hydroxybutyrate (GHB)". 2002. Archived from the original on 31 December 2005. Retrieved 2016-11-20.
- Iversen, Les (2013-10-03). "ACMD advice on the scheduling of GHB" (PDF). UK Home Office. Retrieved 2013-10-23.
- "Circular 001/2015: A Change to the Misuse of Drugs Act 1971: control of AH-7921, LSD–related compounds, tryptamines, and rescheduling of GHB". UK Home Office. 2015.
- "The Misuse of Drugs (Amendment No. 3) (England, Wales and Scotland) Regulations 2014". UK Home Office. 11 December 2014.
- "FOR 30 June 1978 nr 08: Forskrift om narkotika m.v. (Narkotikalisten)".
- Xyrem untersteht dem Bundesgesetz über die Betäubungsmittel und die psychotropen Stoffe[permanent dead link]
- Haller C, Thai D, Jacob P, Dyer JE (2006). "GHB urine concentrations after single-dose administration in humans". Journal of Analytical Toxicology. 30 (6): 360–4. doi:10.1093/jat/30.6.360. PMC 2257868. PMID 16872565.
- Gamma-hydroxybutyrate MS Spectrum
- The Cognitive Enhancement Research Institute – Research findings on GHB and other substances
- EMCDDA Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs
- Erowid GHB Vault (also contains information about addiction and dangers)
- InfoFacts – Rohypnol and GHB (National Institute on Drug Abuse)